Summary: In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c, TIR, TyG), reduced body…
Browsing: Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
Summary: In adults with type 2 diabetes, exenatide and glucagon co-infusion significantly increased myocardial glucose uptake and improved markers of…
First-in-human phase 1 trial finds the oral GLP-1/amylin co-agonist amycretin safe and well tolerated with dose-dependent gastrointestinal effects; weight and glucose changes were exploratory only. PICO summary and expert commentary.
In adults with type 2 diabetes on basal insulin, once-weekly IcoSema was non-inferior to basal-bolus therapy for HbA1c and superior for weight, insulin dose, and hypoglycaemia. PICO summary and expert commentary.
The phase 3a COMBINE 1 trial finds once-weekly IcoSema lowers HbA1c more than insulin icodec alone while cutting hypoglycemia. PICO summary and expert commentary.
Summary: In adults with type 2 diabetes (T2D), mycoprotein and guar gum significantly reduced postprandial glucose (PG) compared to a…
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 equivalent to reference dulaglutide (Trulicity) for HbA1c reduction at 24 weeks. PICO summary and expert commentary.
A prespecified SOUL trial analysis tested whether baseline SGLT2 inhibitor use modified oral semaglutide’s cardiovascular benefit in type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of ONWARDS 1-5 testing whether the efficacy and hypoglycaemia profile of once-weekly insulin icodec versus once-daily basal insulin differs by baseline GLP-1RA or SGLT2i use. PICO summary and expert commentary.
A post hoc analysis of two randomised trials found iGlarLixi produced larger 12-week HbA1c falls and faster time to target than insulin glargine in Asian adults with type 2 diabetes, though without reported between-group significance testing. PICO summary and expert commentary.